Capricor raises $23M in registered direct offering of stock and warrants

CAPRICOR THERAPEUTICS, INC.

Gross proceeds ~$23M from 4,935,621 shares plus warrants at $4.66/unit.
Warrants exercisable at $5.70/share for 7 years, beginning 6 months after issuance.
Investors include Nippon Shinyaku and Highbridge Capital Management.
Net proceeds to fund R&D, manufacturing, working capital; expected to fund HOPE-3 Phase 3 topline data readout.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CAPRICOR THERAPEUTICS, INC. entered into Purchase Agreement with certain institutional investors valued at approximately $23 million (effective 2023-09-29).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $23 million
Effective: 2023-09-29

Exact text from the filing

On September 29, 2023, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Offering”), an aggregate of (a) 4,935,621 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), (the “Shares”) and (b) warrants to purchase 4,935,621 shares of the Company’s common stock (the “Warrants”) to the Purchasers.

View on SEC.gov

631 material agreements filed in the last 30 days. Browse all material agreements →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-016171

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.